MindImmune: $30 Million Series A Closed As Isaac Stoner Becomes CEO
By Amit Chowdhry ● Nov 25, 2025
MindImmune Therapeutics has expanded its Series A financing to $30 million and appointed life sciences entrepreneur Isaac Stoner as its new Chief Executive Officer, marking a significant milestone for the neuroinflammation-focused biotechnology company. The $10.2 million extension adds to earlier Series A commitments from a syndicate that includes Dolby Family Ventures, Pfizer Ventures, Gates Frontier, Slater Technology Fund, RightHill Ventures, the Foundation for a Better World, and other investors. Alongside the leadership transition, Stoner and Reetika Bhardwaj of Dolby Family Ventures will join the company’s Board of Directors.